Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,845 total articles

Aeluma: Buy the Manufacturing Transition - Play for Photonic Scale-Up

Aeluma: Buy the Manufacturing Transition - Play for Photonic Scale-Up

Aeluma is shifting from lab-scale IP to wafer-scale photonic manufacturing. Recent capital raises, equipment purchases, and government contract wins materially de-risk the path to commercialization. The risk-reward is asymmetric for disciplined traders: expensive on sales today but potentially re-rated if production-ready demos and incremental reve…

Crescent Energy: A Quiet Shale Compounder Worth a Tactical Long

Crescent Energy: A Quiet Shale Compounder Worth a Tactical Long

Crescent Energy (CRGY) looks like a mid-cap shale operator the market has underpriced. With a roughly $4.29B market cap, an accretive Vital Energy tie-up, attractive EV/EBITDA and P/B multiples, and a 3%+ yield, Crescent offers a favorable risk/reward for a long trade over the next 180 trading days. The plan: buy at $13.08, stop at $11.20, target $…

GE Aerospace: Investing in Profitable Growth From Emerging Markets

GE Aerospace: Investing in Profitable Growth From Emerging Markets

GE Aerospace combines high-margin aftermarket revenue, strong free cash flow and targeted manufacturing investments that should translate into durable growth. At a market cap near $305B and free cash flow of $7.26B, the stock carries a premium multiple but has several clear catalysts - expanding MRO programs, defense wins and AI-driven maintenance …

Buy VOYG on Defense Momentum; Starlab Optionality Is the Upside

Buy VOYG on Defense Momentum; Starlab Optionality Is the Upside

Voyager Technologies is showing tangible defense revenue momentum and progressing Starlab toward manufacturing after a Commercial Critical Design Review. The stock has pulled back into technical support and carries material upside if NASA awards contracts or Starlab validation continues. We recommend a mid-term long trade with strict risk controls …

Buy Pfizer on the Dip: Income, Cash Flow and a Near-Term Rebound Setup

Buy Pfizer on the Dip: Income, Cash Flow and a Near-Term Rebound Setup

Pfizer offers a compelling short-to-mid-term trade: the stock sits near technical support, yields ~6.3%, and the company produces meaningful free cash flow ($10.375B). With a market cap of roughly $153.4B and an EV/EBITDA of 9.06, the risk-reward for a mid-term rebound is attractive. This note lays out an entry at $26.70, a $30.00 target (45 tradin…

Booking Holdings: Buy the AI Panic - Upgrade to Buy After Overshoot

Booking Holdings: Buy the AI Panic - Upgrade to Buy After Overshoot

Booking Holdings (BKNG) has been sold off on headlines about AI threats to online travel agencies. Fundamentals remain strong - $135.9B market cap, $9.09B free cash flow, and EPS of $170.62 - while technicals show recent support near $4,000. We upgrade to Buy and propose an actionable long trade with a $4,340 entry, $3,900 stop and $5,900 target ov…

Buy the Dip in Dollarama After a Soft Q4: Long-Term Trade Plan

Buy the Dip in Dollarama After a Soft Q4: Long-Term Trade Plan

Dollarama (DLMAF) plunged into oversold territory after a sharp post-quarter selloff. The OTC-listed shares show stretched negativity — RSI 26, price below the 10/20/50 SMAs, and very high short-volume on 03/24/2026 — creating a risk-reward setup for a long trade. This idea is tactical: enter near $120, limit downside with a $104 stop, and aim for …

DHT Has Liquidity—Position for a Q2 Payout Shock (Mid-term Long)

DHT Has Liquidity—Position for a Q2 Payout Shock (Mid-term Long)

DHT's balance-sheet improvement from recent VLCC sales and the arrival of newbuildings into the spot market materially increases the company's optionality for a large Q2 cash distribution. Shares trade at $18.64 with a market cap near $2.97B and a PE of 13.5; a disciplined mid-term long can capture upside if management leans into a special/boosted …

Why Santander's Reset Could Turn a 10x P/E into a Steep Bargain

Why Santander's Reset Could Turn a 10x P/E into a Steep Bargain

Santander trades near $11 with a market cap of $160B and a trailing P/E ~10.9. Recent noise around a UK mortgage exposure and legal inquiries has pressured sentiment. Under the surface, a diversified franchise, improving risk-weighted asset mix, and strategic initiatives in payments and digital banking argue for earnings recovery and multiple re-ra…

Blue Owl: A Tactical Long Against Panic, Not a Systemic Bust

Blue Owl: A Tactical Long Against Panic, Not a Systemic Bust

Blue Owl (OWL) has been punished on private credit redemption headlines and short-term liquidity worries. Fundamentals — significant free cash flow, a sub-$10B enterprise value and an oversold technical set-up — argue for a tactical long. This trade lays out exact entry, stop and target with a 45 trading-day horizon and clear risk controls.

Buy Insmed Now: BRINSUPRI Momentum and a Possible ARIKAYCE Label Expansion Create a Clear Risk/Reward

Buy Insmed Now: BRINSUPRI Momentum and a Possible ARIKAYCE Label Expansion Create a Clear Risk/Reward

Insmed ($139.14) trades at a premium valuation but already owns an approved DPP1 drug with significant peak sales potential and a legacy inhaled antibiotic that could see label expansion. We rate INSM a Strong Buy — entry $140.00, stop $120.00, target $210.00 — for long-term upside if BRINSUPRI adoption continues and ARIKAYCE gains new indications.

Frontline: Ride the Tight Tanker Market Into a Mid-Term Long

Frontline: Ride the Tight Tanker Market Into a Mid-Term Long

Frontline (FRO) is trading near multi-month highs as tanker fundamentals tighten and geopolitical noise keeps freight rates supported. We lay out a mid-term (45 trading days) long trade: enter at $35.50, target $39.50, stop $31.00. Risk is real - freight volatility, oil demand weakness and macro shocks can reverse gains - but the company's recent p…